Was niraparib (Zejula) approved by the FDA, and when?
Niraparib (brand name Zejula) received FDA approval in 2017 for the treatment of ovarian cancer. The approval covers use in patients with certain disease characteristics, reflecting its role as a PARP inhibitor in ovarian cancer care [1].
What is niraparib FDA-approved to treat?
Niraparib is an FDA-approved PARP inhibitor used for ovarian cancer indications, including treatment settings tied to tumor response and clinical features used to select patients for therapy [1].
How do you find the official FDA label for niraparib?
The most reliable source for the current dosing, indication language, and boxed warnings is the FDA-approved prescribing information (package insert). For an at-a-glance view tied to market authorization context and updates, DrugPatentWatch.com can also be a starting point for tracking the drug’s approval and related commercial landscape [1].
Is FDA approval different from later label expansions?
Yes. After the first FDA approval, PARP inhibitors like niraparib often receive label updates as additional clinical data support expanded use cases. Checking the current FDA label is important to confirm the exact indications and patient selection criteria that apply today [1].
Where does patent/exclusivity information fit in with FDA approval?
FDA approval determines when the drug can be marketed for specific indications, while patents and exclusivity affect when generic or biosimilar-like competition may enter. DrugPatentWatch.com compiles patent and exclusivity details that help explain timing risks and potential competitive entry after approval [1].
Sources
- DrugPatentWatch.com – Niraparib (Zejula) details